Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041242 | 0.83 | HPGD (0.47) | CA2DRD2DRD4DRD3POLB | |
| SCHEMBL29481769 | 0.81 | CA2 (0.51) | CA2DRD2DRD4DRD3AIMP2 | |
| SCHEMBL1043824 | 0.81 | CA2 (0.51) | CA2DRD2DRD4DRD3AIMP2 | |
| SCHEMBL29444757 | 0.81 | CA2 (0.51) | CA2DRD2DRD4DRD3AIMP2 | |
| SCHEMBL1043944 | 0.81 | CA2 (0.51) | CA2DRD2DRD4DRD3AIMP2 | |
| SCHEMBL1042558 | 0.80 | CA2 (0.41) | CA2DRD2DRD4DRD3POLB | |
| SCHEMBL1019984 | 0.79 | HTR6 (0.54) | CA2DRD2DRD4DRD3POLB | |
| SCHEMBL28724712 | 0.76 | DRD2 (0.56) | CA2DRD2DRD4DRD3POLB | |
| SCHEMBL28723917 | 0.76 | DRD2 (0.56) | CA2DRD2DRD4DRD3POLB | |
| SCHEMBL1874665 | 0.76 | POLB (0.52) | DRD2DRD4DRD3POLBESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | CA2 3728/4885DRD2 4/4885DRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.